Definitive radiotherapy or chemoradiotherapy results and side effects in elderly bladder cancer patients

Yıl 2019, Cilt: 41 Sayı: 4, 703 - 711, 31.12.2019

Birsen Yücel Eda Erdiş

https://doi.org/10.7197/cmj.vi.643500

Öz

Objective: Bladder cancer is
most commonly observed in elderly patients. In these patients, it is not always
possible to give the necessary treatment for the disease. In this study,
definitive radiotherapy (RT) or chemoradiotherapy (CRT) results and side
effects, as well as prognostic factors, were investigated in elderly bladder
cancer patients.

Method: The results of 36
elderly patients who received definitive RT or CRT for bladder cancer between
the years 2010–2018 in Sivas Oncology Center of Cumhuriyet University Medical
Faculty were analyzed retrospectively.

Results: The median age of the patients was 75 (range, 65–84). Sixteen
patients (44%) underwent RT without chemotherapy and 20 patients (56%) received
CRT. Complete response was detected in 19 (53%) patients. The median survival
was 18 months (range 3–102 months) and the overall 2-year survival rate was
37%. Treatment response (p < .001) and performance status of the patients (p
= .001) were found to be statistically significant prognostic factors in
patients' survival. However, sex, comorbidity, Charlson Comorbidity index, risk
groups, treatment modality (RT vs. CRT), presence of in situ, grade, status of
tumor foci (unifocal vs. multifocal), degree of tumor resection in transurethral
resection of the bladder (TUR-B, complete vs. incomplete resection),
chemotherapy after CRT, concurrent chemotherapy regimen (ciplatin vs.gemcitabine),
RT dose (< 60 Gy vs. ≥60 Gy), and the device used in RT (linac vs.
TomoTherapy) were not statistically significant.

Conclusions: Good performance and completed response to
treatment in elderly bladder cancer patients positively affects survival.

Anahtar Kelimeler

Bladder cancer, elderly patients, radiotherapy, chemoradiotherapy

Kaynakça

• 1. Efstathiou JA and Zietman AL. Bladder Cancer (chapter 54). Gunderson LL and Tepper JE (ed.). Clinical Radiation Oncology (4th Edittion). Elsevier 2016: pp:1096-1120.
• 2. Haskell cancer treatment. 5th ed. Ch. 51. 2001. P:828-45.
• 3. Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992;19:435-53.
• 4. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU International 2002;89:369-73.
• 5. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573-83.
• 6. Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. European Urology 2013;63(1):45-57.
• 7. Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control 2013;20(3):188-99.
• 8. Cahn DB, Ristau BT, Ghiraldi EM, et al. Bladder preservation therapy: a review of the literature and future directions. Urology 2016;96:54-61.
• 9. Schultzel M, Saltzstein SL, Downs TM, et al. Late age (85 years or older) peak incidence of bladder cancer. J Urol (2008);179(4):1302–6.
• 10. Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. Ed. 8 Cham, Switzerland: Springer; 2017.
• 11. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016
• 12. Oken MM, Creech RH, Tormey DC, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
• 13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
• 14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: devel”opment and validation. Journal of Chronic Diseases 1987;40:373-83.
• 15. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. International Journal of Radiation Oncology Biology Physics 1993;25(5):783-90.
• 16. Hagan MP, Witner KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal of Radiation Oncology Biology Physics, 2003;57(3):665-72.
• 17. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology 2000;18(17):3068-77.
• 18. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. International Journal of Radiation Oncology Biology Physics 1993;25(5):783-90.
• 19. Shipley WU, Witner KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. Journal of Clinical Oncology 1998;16(11):3576-83.
• 20. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. The Oncologist 2000;5(6):471-6.
• 21. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73(4):833-7.
• 22. Giacalone NJ, Shipley WU, Rebecca HC, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. European Urology 2017;71(6):952-60.
• 23. Wujanto C, Tey J, Chia D, et al. Radical radiotherapy in older patients with muscle invasive bladder cancer. Journal of Geriatric Oncology 2019;10(2):292-7.
• 24. Lee YT, Wu YT, Yen CC, et al. Concurrent chemoradiotherapy in elderly patients with muscle-invasive bladder cancer: A single-center experience. Journal of Cancer Research and Practice 2016;3(3):73-6.
• 25. Turgeon GA, Souhami L, Cury FL, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. International Journal of Radiation Oncology Biology Physics 2014;88(2):326-31.
• 26. Hsieh CH, Chung SD, Chan PH, et al. (2011). Intensity modulated radiotherapy for elderly bladder cancer patients. Radiation Oncology 2011;6(1):75.
• 27. Korpics MC, Block AM, Martin B, et al. (2017). Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer 2017;123(18):3524-31.